UCB to sponsor trials at ‘giant site without borders’

By Flora Southey contact

- Last updated on GMT

(Image: Getty/oatawa)
(Image: Getty/oatawa)
Neurology and immunology trial participants will undertake "site-less" clinical trials under a partnership between Science 37 and drugmaker UCB.

According to the strategic collaboration, UCB-sponsored studies will use Science 37’s mobile research platform, the Network Oriented Research Assistant (NORA), to offer "site-less" trials.

The decentralized​ "Metasite" clinical trial model engages with subjects remotely to encourage greater retention of participants and reduce recruitment times.

“Science 37 is made up of one-part in-house technology team, the rest is a decentralized physician network who connect directly to patients 24/7/375 using our proprietary mobile platform,” ​explained Science 37 CEO Belinda Tan.

“We think of ourselves as a giant site without borders,” ​she added.

The partnership will also help UCB-sponsored studies reach remote or underserved communities, we were told.

The first ‘site-less’ UCB trial for Paediatric restless leg syndrome (RLS) is expected to begin this year.

Strategic collaborations

Science 37’s Metasite platform is attracting increased attention in the clinical development space. 

In December last year, Otsuka Pharmaceutical announced​ a strategic collaboration to explore the patient-centric trial method.

Additionally, in March 2018 Novartis​ – an early investor​ in Science 37 – committed​ to conducting up to ten clinical trials to scale up the "site-less" model.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us


View more